- 询价
- 加拿大TRC
- 188062-50-2
- 2025年07月16日
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 库存：
大量
- 规格：
25G
北京京京未来科技发展有限公司专业供应加拿大TRC标准品。
TRC是加拿大全资公司，世界领先的有机化学品（包括碳水化学、芳香化学、氮磷硫化学、放射性同位素及同位素标记物等）制造商，建立于1982年，占地55,000平方英尺，包括研究实验室和生产车间，主要用于生物学、医学、药学、临床诊断和试验方面的研究和生产。TRC提供生化研究的有机化学品，用于生物技术，制药，诊断。研究特殊化学品。提供从g级到kg级别的定制合同。
A105000 ABACAVIR SULFATE
(1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol Sulfate;
Ziagen;
C28H38N12O6S
A nucleoside reverse transcriptase inhibitor (NRTI).
Daluge, S.M., et al.: Antimicrob. Ag. Chemother., 41, 1082 (1997), Foster, R.H., et al.: Drugs, 55, 729 (1998), Staszewski, S., et al.: J. Am. Med. Assoc.,
285, 1155 (2001),
670.74 5 mg
188062-50-2
222-225°C
50 mg $
m.p.,
CAS#
m.w.,
A105002 ABACAVIR-D4
(1S,4R)-4-[2-Amino-6-[(cyclopropyl-d4)amino]-9H-purin-9-yl]-2-cyclopentene-1-methanol;
Ziagen-d4;
C14H14D4N6O
A labelled nucleoside reverse transcriptase inhibitor (NRTI).
Daluge, S.M., et al.: Antimicrob. Ag. Chemother., 41, 1082 (1997), Foster, R.H., et al.: Drugs, 55, 729 (1998), Staszewski, S., et al.: J. Am. Med. Assoc.,
285, 1155 (2001),
290.36 222-225°C 1 mg
10 mg
m.w., m.p.,
A105010 ABACAVIR 5’- -D-GLUCURONIDE
[(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopenten-1-yl]methyl- -D-Gluco
pyranosiduronic Acid; Abacavir 5’-Glucuronide;
C20H26N6O7
A metabolite of Abacavir.
Hoetelmans, R., et al.: Pharm. World Sci., 19, 159 (1997), Beach, J., et al.: Clin. Ther., 20, 2 (1998), McDowell, J., et al.: Antimicrob. Agents
Chemother., 43, 2855 (1999),
462.46 1 mg
384329-76-4
>211°C (dec.)
10 mg
CAS#
m.w.,
A105030 ABACAVIR 5’-(2,3,4-TRI-O-ISOBYTYRYL)- -D-GLUCURONIC ACID METHYL
ESTER
C33H46N6O10
An intermediate in the preparation of Abacavir metabolites
686.75 1 mg
10 mg
A107000 ABAMECTIN
AVERMECTIN B1; MK-936; AGRI-MEK; AVID; ZEPHYR;
C48H72O14
Mixture of avermectins, containing at least 80 of avermectin B1a (C48H72O14) and not more than 20 of avermectin B1b (C47H70O14). Used as acaricide,
insecticide.
Wang, S., et al.: Prog. Clin. Biol. Res., 97, 373 (1982), Greenblatt, J.A., et al.: J. Agric. Entomol., 3, 233 (1986), Drexler, G., et al.: Eur. J. Pharmacol.,
99, 269 (1984),
873.08 10 mg
71751-41-2
150-1550C
100 mg
m.p.,
CAS#
m.w.
A108500 ABIRATERONE ACETATE
(3β)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol Acetate (Ester); CB 7630;
C26H33NO2
A novel steroidal inhibitor of human Cytochrome P450(17 -Hydroxylase-C17,20-lyase): potential agent for the treatment of prostatic cancer.
Denis, L., et al.: Cancer, 72, 3888 (1993), Potter, G.A., et al.: J. Med. Chem., 38, 2463 (1995), Denmeade, S., et al.: Nat. Rev., 2, 389
(2002), Scher, H., et al.: J. Clin. Oncol., 23, 8253 (2005),
391.55 5 mg
154229-18-2
127-130°C
50 mg
CAS#
m.w.,
A108502 ABIRATERONE ACETATE-D4
(3β)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol Acetate-d4 (Ester); CB 7630-d4;
C26H29D4NO2
A novel steroidal inhibitor of human Cytochrome P450(17 -Hydroxylase-C17,20-lyase): potential agent for the treatment of prostatic cancer.
Denis, L., et al.: Cancer, 72, 3888 (1993), Potter, G.A., et al.: J. Med. Chem., 38, 2463 (1995), Denmeade, S., et al.: Nat. Rev., 2, 389
(2002), Scher, H., et al.: J. Clin. Oncol., 23, 8253 (2005),
m.w., 395.57 133-135°C 10 mg
A110000 (+)-CIS,TRANS-ABSCISIC ACID, 98
(S-(Z,E)])-5-(1-Hydroxy-2,6,6-trimethyl)-4-oxo-2-cyclohexen-1-yl-3-methyl-2,4-pentadienoic
Acid; S-ABA; Dormin;
C15H20O4
The natural isomer of the abscission-accelerating plant hormone.
Krochko, J.E., et al.: Plant Physiol., 118, 849 (1998), Jacobsen, J.V., et al.: Psysiol. Plant., 115, 428 (2002),
264.32 10 mg
21293-29-8
161-163C
100 mg
m.p.,
CAS#
m.w.,
A110002 (+)CIS,TRANS-ABSCISIC ACID-D6
[S-(Z,E)]-5-[1-Hydroxy-6,6-dimethyl-2-(methyl-d6)-4-oxo-2-cyclohexen-1-yl]-3-methyl-2,4-pent
adienoic Acid; S-ABA-d6; Dormin-d6;
C15H14D6O4
The natural isomer of the abscission-accelerating plant hormone.
Krochko, J.E., et al.: Plant Physiol., 118, 849 (1998), Jacobsen, J.V., et al.: Psysiol. Plant., 115, 428 (2002),
270.35 161-163°C 1 mg
10 mg
m.p.,
CAS#
m.w.,
A112500 ABT 263
4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(
4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]
benzamide;
C47H55ClF3N5O6S3
A novel inhibitor of antiapoptotic BCL-2 proteins; a new promising anticancer drug candidate.
Adams, J., et al.: Science, 281, 1322 (1998), Degterev, A., et al.: Nat. Cell. Biol., 3, 173 (2001), Kitada, S., et al.: J. Med. Chem., 46, 4259 (2003),
Danial, N., et al.: Clin. Cancer Res., 13, 7254 (2007),
974.61 5 mg
923564-51-6
114-116°C
50 mg
CAS#
m.w.,
Toronto Research Chemicals Inc., Tel: 416-665-9696
2 Brisbane Rd., Fax: 416-665-4439
North York, ON, e-mail:torresch@interlog.com
Canada, M3J 2J8 URL: www.trc-canada.com
Toronto Research Chemicals Inc.
A112502 ABT 263-D8
4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(
4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]
benzamide-d8;
C47H47D8ClF3N5O6S3
A novel inhibitor of antiapoptotic BCL-2 proteins; a new promising anticancer drug candidate.
Adams, J., et al.: Science, 281, 1322 (1998), Degterev, A., et al.: Nat. Cell. Biol., 3, 173 (2001), Kitada, S., et al.: J. Med. Chem., 46, 4259 (2003),
Danial, N., et al.: Clin. Cancer Res., 13, 7254 (2007),
982.66 102-107°C 1 mg
10 mg
A112550 ABT 737
4-[4-[(4’-Chloro[1,1’-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(ph
enylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide;
C42H45ClN6O5S2
A selective inhibitor of BCL-2, in small cell lung cancer. ABT-737 induced dramatic regressions in tumors derived from some SCLC cell lines.
Ikegaki, N., et al.: Cancer Res., 54, 6 (1994), Kaiser, U., et al.: Lung Cancer, 15, 31 (1996), Rudin, C., et al.: J. Clin. Oncol., 22, 1110 ( 2004),
Konopleva, M., et al.: Cancer Cell, 10, 375 (2006), Trudel, S., et al.: Clin. Cancer Res., 13, 621 (2007),
813.43 2.5 mg
852808-04-9
152-154°C
25 mg
CAS#
m.w.,
A112552 ABT 737-D8
4-[4-[(4’-Chloro[1,1’-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(ph
enylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide-d8;
C42H37D8ClN6O5S2
A selective inhibitor of BCL-2, in small cell lung cancer. ABT-737 induced dramatic regressions in tumors derived from some SCLC cell lines.
Ikegaki, N., et al.: Cancer Res., 54, 6 (1994), Kaiser, U., et al.: Lung Cancer, 15, 31 (1996), Rudin, C., et al.: J. Clin. Oncol., 22, 1110 ( 2004),
Konopleva, M., et al.: Cancer Cell, 10, 375 (2006), Trudel, S., et al.: Clin. Cancer Res., 13, 621 (2007),
821.48 148-150°C 1 mg
10 mg
A112580 ABT 888
2-[(2R)-2-Methyl-2-pyrrolidinyl]-1H-benzimidazole-7-carboxamide; A 861695;
C13H16N4O
ABT-888 is a potent, orally bioavailable PARP-1/-2 inhibitor shown to potentiate DNA damaging agents. The ability to potentiate temozolomide (TMZ)
and develop a biological marker for PARP inhibition was evaluated in vivo.
Virag, L., et al.: Pharmacol. Rev., 54, 375 (2002), Tentori, L., et al.: Clin. Cancer Res., 9, 5370 (2003), Kim, M., et al.: Cell, 119, 803 (2004), Tentori,
L., et al.: Pharmacol. Res., 52, 25 (2005),
244.29 10 mg
912444-00-9版面有限，更多加拿大TRC标准品欢迎您来电咨询。
TRC是加拿大全资公司，世界领先的有机化学品（包括碳水化学、芳香化学、氮磷硫化学、放射性同位素及同位素标记物等）制造商，建立于1982年，占地55,000平方英尺，包括研究实验室和生产车间，主要用于生物学、医学、药学、临床诊断和试验方面的研究和生产。TRC提供生化研究的有机化学品，用于生物技术，制药，诊断。研究特殊化学品。提供从g级到kg级别的定制合同。
A105000 ABACAVIR SULFATE
(1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol Sulfate;
Ziagen;
C28H38N12O6S
A nucleoside reverse transcriptase inhibitor (NRTI).
Daluge, S.M., et al.: Antimicrob. Ag. Chemother., 41, 1082 (1997), Foster, R.H., et al.: Drugs, 55, 729 (1998), Staszewski, S., et al.: J. Am. Med. Assoc.,
285, 1155 (2001),
670.74 5 mg
188062-50-2
222-225°C
50 mg $
m.p.,
CAS#
m.w.,
A105002 ABACAVIR-D4
(1S,4R)-4-[2-Amino-6-[(cyclopropyl-d4)amino]-9H-purin-9-yl]-2-cyclopentene-1-methanol;
Ziagen-d4;
C14H14D4N6O
A labelled nucleoside reverse transcriptase inhibitor (NRTI).
Daluge, S.M., et al.: Antimicrob. Ag. Chemother., 41, 1082 (1997), Foster, R.H., et al.: Drugs, 55, 729 (1998), Staszewski, S., et al.: J. Am. Med. Assoc.,
285, 1155 (2001),
290.36 222-225°C 1 mg
10 mg
m.w., m.p.,
A105010 ABACAVIR 5’- -D-GLUCURONIDE
[(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopenten-1-yl]methyl- -D-Gluco
pyranosiduronic Acid; Abacavir 5’-Glucuronide;
C20H26N6O7
A metabolite of Abacavir.
Hoetelmans, R., et al.: Pharm. World Sci., 19, 159 (1997), Beach, J., et al.: Clin. Ther., 20, 2 (1998), McDowell, J., et al.: Antimicrob. Agents
Chemother., 43, 2855 (1999),
462.46 1 mg
384329-76-4
>211°C (dec.)
10 mg
CAS#
m.w.,
A105030 ABACAVIR 5’-(2,3,4-TRI-O-ISOBYTYRYL)- -D-GLUCURONIC ACID METHYL
ESTER
C33H46N6O10
An intermediate in the preparation of Abacavir metabolites
686.75 1 mg
10 mg
A107000 ABAMECTIN
AVERMECTIN B1; MK-936; AGRI-MEK; AVID; ZEPHYR;
C48H72O14
Mixture of avermectins, containing at least 80 of avermectin B1a (C48H72O14) and not more than 20 of avermectin B1b (C47H70O14). Used as acaricide,
insecticide.
Wang, S., et al.: Prog. Clin. Biol. Res., 97, 373 (1982), Greenblatt, J.A., et al.: J. Agric. Entomol., 3, 233 (1986), Drexler, G., et al.: Eur. J. Pharmacol.,
99, 269 (1984),
873.08 10 mg
71751-41-2
150-1550C
100 mg
m.p.,
CAS#
m.w.
A108500 ABIRATERONE ACETATE
(3β)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol Acetate (Ester); CB 7630;
C26H33NO2
A novel steroidal inhibitor of human Cytochrome P450(17 -Hydroxylase-C17,20-lyase): potential agent for the treatment of prostatic cancer.
Denis, L., et al.: Cancer, 72, 3888 (1993), Potter, G.A., et al.: J. Med. Chem., 38, 2463 (1995), Denmeade, S., et al.: Nat. Rev., 2, 389
(2002), Scher, H., et al.: J. Clin. Oncol., 23, 8253 (2005),
391.55 5 mg
154229-18-2
127-130°C
50 mg
CAS#
m.w.,
A108502 ABIRATERONE ACETATE-D4
(3β)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol Acetate-d4 (Ester); CB 7630-d4;
C26H29D4NO2
A novel steroidal inhibitor of human Cytochrome P450(17 -Hydroxylase-C17,20-lyase): potential agent for the treatment of prostatic cancer.
Denis, L., et al.: Cancer, 72, 3888 (1993), Potter, G.A., et al.: J. Med. Chem., 38, 2463 (1995), Denmeade, S., et al.: Nat. Rev., 2, 389
(2002), Scher, H., et al.: J. Clin. Oncol., 23, 8253 (2005),
m.w., 395.57 133-135°C 10 mg
A110000 (+)-CIS,TRANS-ABSCISIC ACID, 98
(S-(Z,E)])-5-(1-Hydroxy-2,6,6-trimethyl)-4-oxo-2-cyclohexen-1-yl-3-methyl-2,4-pentadienoic
Acid; S-ABA; Dormin;
C15H20O4
The natural isomer of the abscission-accelerating plant hormone.
Krochko, J.E., et al.: Plant Physiol., 118, 849 (1998), Jacobsen, J.V., et al.: Psysiol. Plant., 115, 428 (2002),
264.32 10 mg
21293-29-8
161-163C
100 mg
m.p.,
CAS#
m.w.,
A110002 (+)CIS,TRANS-ABSCISIC ACID-D6
[S-(Z,E)]-5-[1-Hydroxy-6,6-dimethyl-2-(methyl-d6)-4-oxo-2-cyclohexen-1-yl]-3-methyl-2,4-pent
adienoic Acid; S-ABA-d6; Dormin-d6;
C15H14D6O4
The natural isomer of the abscission-accelerating plant hormone.
Krochko, J.E., et al.: Plant Physiol., 118, 849 (1998), Jacobsen, J.V., et al.: Psysiol. Plant., 115, 428 (2002),
270.35 161-163°C 1 mg
10 mg
m.p.,
CAS#
m.w.,
A112500 ABT 263
4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(
4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]
benzamide;
C47H55ClF3N5O6S3
A novel inhibitor of antiapoptotic BCL-2 proteins; a new promising anticancer drug candidate.
Adams, J., et al.: Science, 281, 1322 (1998), Degterev, A., et al.: Nat. Cell. Biol., 3, 173 (2001), Kitada, S., et al.: J. Med. Chem., 46, 4259 (2003),
Danial, N., et al.: Clin. Cancer Res., 13, 7254 (2007),
974.61 5 mg
923564-51-6
114-116°C
50 mg
CAS#
m.w.,
Toronto Research Chemicals Inc., Tel: 416-665-9696
2 Brisbane Rd., Fax: 416-665-4439
North York, ON, e-mail:torresch@interlog.com
Canada, M3J 2J8 URL: www.trc-canada.com
Toronto Research Chemicals Inc.
A112502 ABT 263-D8
4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(
4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]
benzamide-d8;
C47H47D8ClF3N5O6S3
A novel inhibitor of antiapoptotic BCL-2 proteins; a new promising anticancer drug candidate.
Adams, J., et al.: Science, 281, 1322 (1998), Degterev, A., et al.: Nat. Cell. Biol., 3, 173 (2001), Kitada, S., et al.: J. Med. Chem., 46, 4259 (2003),
Danial, N., et al.: Clin. Cancer Res., 13, 7254 (2007),
982.66 102-107°C 1 mg
10 mg
A112550 ABT 737
4-[4-[(4’-Chloro[1,1’-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(ph
enylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide;
C42H45ClN6O5S2
A selective inhibitor of BCL-2, in small cell lung cancer. ABT-737 induced dramatic regressions in tumors derived from some SCLC cell lines.
Ikegaki, N., et al.: Cancer Res., 54, 6 (1994), Kaiser, U., et al.: Lung Cancer, 15, 31 (1996), Rudin, C., et al.: J. Clin. Oncol., 22, 1110 ( 2004),
Konopleva, M., et al.: Cancer Cell, 10, 375 (2006), Trudel, S., et al.: Clin. Cancer Res., 13, 621 (2007),
813.43 2.5 mg
852808-04-9
152-154°C
25 mg
CAS#
m.w.,
A112552 ABT 737-D8
4-[4-[(4’-Chloro[1,1’-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(ph
enylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide-d8;
C42H37D8ClN6O5S2
A selective inhibitor of BCL-2, in small cell lung cancer. ABT-737 induced dramatic regressions in tumors derived from some SCLC cell lines.
Ikegaki, N., et al.: Cancer Res., 54, 6 (1994), Kaiser, U., et al.: Lung Cancer, 15, 31 (1996), Rudin, C., et al.: J. Clin. Oncol., 22, 1110 ( 2004),
Konopleva, M., et al.: Cancer Cell, 10, 375 (2006), Trudel, S., et al.: Clin. Cancer Res., 13, 621 (2007),
821.48 148-150°C 1 mg
10 mg
A112580 ABT 888
2-[(2R)-2-Methyl-2-pyrrolidinyl]-1H-benzimidazole-7-carboxamide; A 861695;
C13H16N4O
ABT-888 is a potent, orally bioavailable PARP-1/-2 inhibitor shown to potentiate DNA damaging agents. The ability to potentiate temozolomide (TMZ)
and develop a biological marker for PARP inhibition was evaluated in vivo.
Virag, L., et al.: Pharmacol. Rev., 54, 375 (2002), Tentori, L., et al.: Clin. Cancer Res., 9, 5370 (2003), Kim, M., et al.: Cell, 119, 803 (2004), Tentori,
L., et al.: Pharmacol. Res., 52, 25 (2005),
244.29 10 mg
912444-00-9版面有限，更多加拿大TRC标准品欢迎您来电咨询。
北京京京未来科技发展有限公司全线供应加拿大TRC公司标准品，质优价廉。
欢迎来电咨询：010-57208557 张硕：15510537254
欢迎来电咨询：010-57208557 张硕：15510537254
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验相关实验
Diego的Illumina公司（光纤芯片技术的主要开发者）、Baylor医学院、加拿大Quebec基因组机构、日本东京大学、中国科学院北京基因组研究所和英国Wellcome Trust Sanger研究所间的国际合作研究。然而，大规模SNPs研究的一个主要障碍是现有技术的低效率和高成本。光纤芯片技术将高度并行样本处理、可扩展自动控制与小型化实验平台结合在一起，为解决这一问题提供了很好的方案[8]。该系统采用高密度微阵列（小珠阵列）技术，结合高通量、高效率的样品制备与扩增方法在整体集成环境中实现了高度
Diego的Illumina公司（光纤芯片技术的主要开发者）、Baylor医学院、加拿大Quebec基因组机构、日本东京大学、中国科学院北京基因组研究所和英国Wellcome Trust Sanger研究所间的国际合作研究。然而，大规模SNPs研究的一个主要障碍是现有技术的低效率和高成本。光纤芯片技术将高度并行样本处理、可扩展自动控制与小型化实验平台结合在一起，为解决这一问题提供了很好的方案[8]。该系统采用高密度微阵列（小珠阵列）技术，结合高通量、高效率的样品制备与扩增方法在整体集成环境中实现了高度
上从而阻遏转录起始。乳糖的类似物IPTG可以和lacI产物结合，使其构象改变离开lacO，从而激活转录。这种可诱导的转录调控成为了大肠杆菌表达系统载体构建的常用元件。tac启动子是trp启动子和lacUV5的拼接杂合启动子，且转录水平更高，比lacUV5更优越。trc启动子是trp启动子和lac启动子的拼合启动子，同样具有比trp更高的转录效率和受lacI阻遏蛋白调控的强启动子特性。在常规的大肠杆菌中，lacI阻遏蛋白表达量不高，仅能满足细胞自身的lac操纵子，无法应付多拷贝的质粒的需求，导致非诱导
技术资料暂无技术资料 索取技术资料
加拿大TRC标准品
询价
